Iomai Stockholders Approve Merger With Intercell Subsidiary
August 01 2008 - 9:18AM
PR Newswire (US)
GAITHERSBURG, Md., Aug. 1 /PRNewswire-FirstCall/ -- Iomai
Corporation (NASDAQ:IOMI) announced today that its stockholders
approved the merger of Iomai with a wholly-owned subsidiary of
Intercell AG. Approximately 71.6 percent of Iomai's outstanding
shares entitled to vote at the special meeting approved the merger,
representing approximately 99.9 percent of the votes cast. The
transaction remains subject to certain closing conditions. Assuming
satisfaction of the remaining conditions, the transaction is
anticipated to be completed on or about Aug. 5, 2008. ABOUT IOMAI
CORPORATION Iomai Corporation discovers and develops vaccines and
immune system stimulants, delivered via a novel, needle-free
technology called transcutaneous immunization (TCI). TCI,
discovered by researchers at the Walter Reed Army Institute of
Research, taps into the unique benefits of a major group of
antigen-presenting cells found in the outer layers of the skin
(Langerhans cells) to generate an enhanced immune response. Iomai
is leveraging TCI to enhance the efficacy of existing vaccines,
develop new vaccines that are viable only through transcutaneous
administration and expand the global vaccine market. Iomai
currently has four product candidates in development: three
targeting influenza and pandemic flu and one to prevent travelers'
diarrhea. For more information on Iomai, please visit
http://www.iomai.com/. DATASOURCE: Iomai Corporation CONTACT:
Stanley C. Erck, President and Chief Executive Officer of Iomai
Corporation, +1-301-556-4500, ; or Brian Reid of WeissComm
Partners, Inc., +1-703-402-3626, , for Iomai Corporation Web site:
http://www.iomai.com/
Copyright
Iomai Corp (MM) (NASDAQ:IOMI)
Historical Stock Chart
From Jul 2024 to Aug 2024
Iomai Corp (MM) (NASDAQ:IOMI)
Historical Stock Chart
From Aug 2023 to Aug 2024